Acambis PLC’s Smallpox Vaccine Meets Main Goal Says FDA Staff

May 15, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON, May 15 (Reuters) - An experimental smallpox vaccine made by Acambis Plc's (ACM.L: Quote, Profile , Research) proved to be no worse than an older product no longer on the market, U.S. regulatory staff said in a review released on Tuesday.

>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Food and Drug Administration (FDA)